Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ro-associated Y4 small cytoplasmic RNA pseudogene 3 (RNY4P3) is a member of the Y RNA pseudogene family. Y RNAs are a class of small non-coding RNAs involved in the formation of ribonucleoprotein complexes with the RO60 autoantigen protein and others[1][3]. The canonical Y RNAs (RNY1, RNY3, RNY4, RNY5) are implicated in RNA stability, DNA replication initiation, and innate immunity[1][3][4]. In contrast, RNY4P3 is a **pseudogene**—a non-functional genomic segment derived from RNY4, lacking evidence for protein coding, functional RNA, or interaction with cellular pathways. While a few Y RNA pseudogenes are *transcribed*, most are not and their biological significance, if any, is uncharacterized[1]. Current literature and curated gene nomenclature do not recognize RNY4P3 as a validated therapeutic target or biomarker. The confusion arises because many sources discuss Y RNAs or canonical RNY4 functions, not the pseudogene RNY4P3 itself.
Not applicable
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ro-associated Y4 small cytoplasmic RNA pseudogene 3 (RNY4P3).